Roche Holding AG





Real-time Estimate Cboe Europe 08:37:08 2024-04-19 am EDT 5-day change 1st Jan Change
220.2 CHF +0.11% Intraday chart for Roche Holding AG -2.13% -9.94%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Roche: approval in lung cancer in the United States CF
Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine MT
Roche's Lung-Cancer Drug Alecensa Gets New FDA Approval DJ
Roche's Early-stage Lung Cancer Treatment Alecensa Wins US FDA Nod MT
Roche's Genentech Gets FDA Approval for Lung-Cancer Treatment DJ
Roche’s Multiple Sclerosis Injection Controls Relapses, Brain Lesions in Late-stage Trial MT
Roche: positive phase III results in MS CF
Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab) CI
ROCHE HOLDINGS AG : JP Morgan reiterates its Sell rating ZD
Roche: positive phase III data in lymphoma CF
Roche's Late-stage Trial for Columvi Antibody Meets Primary Survival Endpoint in B-cell Lymphoma MT
Roche's Columvi Meets Main Goal in Lymphoma Phase 3 Trial DJ
ROCHE HOLDINGS AG : JP Morgan reaffirms its Sell rating ZD
Swiss Market Index Falls as ECB Signals June Rate Cut MT
ROCHE HOLDINGS AG : Berenberg reiterates its Neutral rating ZD
Roche: designation for Alzheimer's test CF
Roche, Eli Lilly Alzheimer's Blood Test to Get Expedited FDA Review DJ
Roche, Eli Lilly's Elecsys Blood Test Secures US FDA's Breakthrough Device Designation MT
Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis CI
Swiss Market Index Little Changed; Barry Callebaut Shines on Revenue Jump MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark MT
Roche: CE mark for Enhertu companion test CF
Novartis to cut 680 jobs in product development RE
ROCHE HOLDINGS AG : UBS reiterates its Neutral rating ZD
Chart Roche Holding AG
More charts
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
220 CHF
Average target price
281.6 CHF
Spread / Average Target
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. News Roche Holding AG
  5. Roche Explores Sale of Lung Disease Treatment After Declining Sales